Jun 6 |
How Alphabet Could Become the Next $3 Trillion Stock
|
Jun 6 |
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
|
Jun 6 |
Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO
|
Jun 6 |
FDA suggests safety warning for Eli Lilly Alzheimer’s drug
|
Jun 6 |
In review of Lilly Alzheimer’s drug, FDA staff focus on safety, patient selection
|
Jun 6 |
Alphabet’s next CFO Anat Ashkenazi ‘fills a void’ for the company at key time during AI Revolution, says top analyst
|
Jun 6 |
Shares in Wegovy-maker Novo Nordisk climb, touching record high levels
|
Jun 5 |
Eli Lilly snaps six straight days of gains, trades in the red
|
Jun 5 |
Google And Eli Lilly Have Things In Common Besides Being Mutual Fund Favorites
|
Jun 5 |
Google Parent Alphabet Poaches Eli Lilly Finance Chief Ashkenazi
|